Cocrystal Pharma Reports Financial Results and Updates on Antiviral Drug-Development ProgramsOn November 13, 2024, Cocrystal Pharma, Inc. (NASDAQ: COCP) provided an overview of its financial results for the third quarter of 2024 and delivered updates
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cocrystal Pharma’s 8K filing here. Cocrystal Pharma Company Profile (Get Free Report) Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic […]
More Stories
Cassady Schiller Wealth Management LLC Acquires 1,337 Shares of Exxon Mobil Co. (NYSE:XOM)
Cassady Schiller Wealth Management LLC raised its holdings in Exxon Mobil Co. (NYSE:XOM – Free Report) by 14.9% during the...
S&CO Inc. Has $4.06 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)
S&CO Inc. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 24.5% during the 3rd...
S&CO Inc. Decreases Holdings in AT&T Inc. (NYSE:T)
S&CO Inc. lowered its position in AT&T Inc. (NYSE:T – Free Report) by 24.0% during the third quarter, HoldingsChannel.com reports....
Lucid Diagnostics Announces Redemption of Senior Convertible Note and Issuance of 2024 Convertible Notes
Lucid Diagnostics Inc. (NASDAQ: LUCD) recently disclosed in an 8-K SEC filing dated November 8, 2024, that the company has...
Atlanta Consulting Group Advisors LLC Raises Stock Position in Marathon Petroleum Co. (NYSE:MPC)
Atlanta Consulting Group Advisors LLC boosted its position in Marathon Petroleum Co. (NYSE:MPC – Free Report) by 2.5% during the...
Shore Bancshares, Inc. (NASDAQ:SHBI) Short Interest Down 18.0% in October
Shore Bancshares, Inc. (NASDAQ:SHBI – Get Free Report) was the recipient of a significant drop in short interest in the...